EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, SNTI: Senti Biosciences Inc

27 Oct 25 15:46
LAST:

2.180

CHANGE:
 0.08		OPEN:
2.080		HIGH:
2.230		ASK:
0.000		VOLUME:
57.8K
CHG(%):
3.81		PREV:
2.100		LOW:
2.072		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Oct 252.0802.2302.0722.18057.8K
24 Oct 252.0002.1702.0002.080117.7K
23 Oct 252.0002.0611.9502.00042.0K
22 Oct 252.0502.1001.9201.980133.0K
21 Oct 252.1102.1562.0502.05064.7K
20 Oct 252.1902.2752.1202.140167.8K
17 Oct 252.1002.1902.0702.150135.3K
16 Oct 252.3102.5502.1002.180404.5K
15 Oct 252.1402.3901.8002.310849.4K
14 Oct 251.7602.4401.7142.0802.72M

COMPANY PROFILE

Name:Senti Biosciences Inc
About:Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:2 Corporate Drive, South San Francisco, CA, United States, 94080
Website:https://www.sentibio.com
CUSIP:81726A100
CIK:0001854270
ISIN:US81726A1007
FIGI:BBG010WX7ZB3

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:2.065.8%
MA10:2.123.0%
MA20:1.8816.0%
MA50:1.6234.8%
MA100:1.8617.1%
MA200:2.7526.1%
STO9:37.72
STO14:59.20
RSI14:64.86 
WPR14:-18.25 
MTM14:0.42
ROC14:0.23 
ATR:0.24 
Week High:2.284.4%
Week Low:1.9213.5%
Month High:2.5517.0%
Month Low:1.3826.1%
Year High:16.94677.1%
Year Low:1.2673.0%

RECENT SPLITS

Date Ratio
18 Jul 20241-10